MX2021002804A - Terapias de combinacion. - Google Patents
Terapias de combinacion.Info
- Publication number
- MX2021002804A MX2021002804A MX2021002804A MX2021002804A MX2021002804A MX 2021002804 A MX2021002804 A MX 2021002804A MX 2021002804 A MX2021002804 A MX 2021002804A MX 2021002804 A MX2021002804 A MX 2021002804A MX 2021002804 A MX2021002804 A MX 2021002804A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- combination therapies
- inhibitor
- subject
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a terapias de combinación para tratar cánceres KRas G12C. En particular, la presente invención se refiere a métodos para tratar el cáncer en un sujeto que lo necesita, que comprende administrar al sujeto una cantidad terapéuticamente eficaz de una combinación de un inhibidor de SHP-2 y un inhibidor de KRAS G12C de Fórmula (I), Fórmula I-A o Fórmula I-B, composiciones farmacéuticas que comprenden cantidades terapéuticamente eficaces de los inhibidores, kits que comprenden las composiciones y métodos de uso para estos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862775628P | 2018-12-05 | 2018-12-05 | |
PCT/US2019/064707 WO2020118066A1 (en) | 2018-12-05 | 2019-12-05 | Combination therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002804A true MX2021002804A (es) | 2021-07-15 |
Family
ID=70973971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002804A MX2021002804A (es) | 2018-12-05 | 2019-12-05 | Terapias de combinacion. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220079947A1 (es) |
EP (1) | EP3890716A4 (es) |
JP (1) | JP2022509724A (es) |
KR (1) | KR20210113587A (es) |
CN (1) | CN113164418A (es) |
AU (1) | AU2019392683A1 (es) |
CA (1) | CA3112129A1 (es) |
EA (1) | EA202190630A1 (es) |
IL (1) | IL281348A (es) |
MX (1) | MX2021002804A (es) |
SG (1) | SG11202102357RA (es) |
WO (1) | WO2020118066A1 (es) |
ZA (1) | ZA202102016B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3849536A4 (en) * | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
JP2022500379A (ja) * | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス, インコーポレイテッド | 組み合わせ療法 |
US20220152026A1 (en) * | 2019-02-12 | 2022-05-19 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
TWI752580B (zh) * | 2019-08-07 | 2022-01-11 | 大陸商北京加科思新藥研發有限公司 | Kras突變蛋白抑制劑 |
CN112694475A (zh) | 2019-10-23 | 2021-04-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
CN112778301A (zh) * | 2019-11-07 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
TW202144349A (zh) * | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | 作為kras抑制劑的雜環化合物的製備及其應用方法 |
KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
AU2021298154A1 (en) * | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
KR20230081726A (ko) | 2020-09-03 | 2023-06-07 | 레볼루션 메디슨즈, 인크. | Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도 |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
JP2023554471A (ja) * | 2020-12-22 | 2023-12-27 | ノバルティス アーゲー | Kras g12c阻害剤を含む医薬組み合わせ及び癌の治療のためのkras g12c阻害剤の使用 |
WO2022165142A1 (en) * | 2021-01-29 | 2022-08-04 | Mirati Therapeutics, Inc. | Combination therapies |
WO2022247760A1 (zh) * | 2021-05-22 | 2022-12-01 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物,及其制备和治疗用途 |
TW202317100A (zh) * | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
WO2023168036A1 (en) * | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
WO2024076672A1 (en) * | 2022-10-05 | 2024-04-11 | Amgen Inc. | Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof |
WO2024081363A1 (en) * | 2022-10-12 | 2024-04-18 | Revolution Medicines, Inc. | Composition comprising a first ras inhibitor, second ras inhibitor and a shp2 inhibitor for use in the treatment of cancer |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613785B2 (en) | 1998-07-21 | 2003-09-02 | Smithkline Beecham Plc | Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
US20040043434A1 (en) | 2002-06-13 | 2004-03-04 | Gen-Sheng Feng | Shp-2 tyrosine phosphatase and embryonic stem cell differentiation |
AU2003291254A1 (en) | 2002-11-05 | 2004-06-07 | Mount Sinai School Of Medicine Of New York University ; | Ptpn11 (shp-2) mutations and cancer |
US20080058431A1 (en) | 2004-03-26 | 2008-03-06 | Gen-Sheng Feng | Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders |
EP1728790A1 (en) | 2005-06-01 | 2006-12-06 | Max-Delbrück-Centrum Für Molekulare Medizin | Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases |
US7547760B2 (en) | 2006-07-03 | 2009-06-16 | West Virginia University | Peptides and chemical compound for inhibition of SHP2 function |
US9174969B2 (en) | 2008-07-21 | 2015-11-03 | University Of South Florida | Indoline scaffold SHP-2 inhibitors and cancer treatment method |
NL2008335A (en) | 2011-04-07 | 2012-10-09 | Asml Netherlands Bv | Lithographic apparatus, device manufacturing method, and method of correcting a mask. |
RS58192B1 (sr) | 2012-11-21 | 2019-03-29 | Janssen Biotech Inc | Bispecifična egfr/c-met antitela |
EP3094629B1 (en) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
EP3094627B1 (en) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US10532977B2 (en) | 2015-06-01 | 2020-01-14 | Indiana University Research And Technology Corporation | Small molecule inhibitors of protein tyrosine phosphatases and uses thereof |
JP6878316B2 (ja) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Shp2の活性を阻害するための化合物および組成物 |
ES2805232T3 (es) | 2015-06-19 | 2021-02-11 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
US10256121B2 (en) | 2015-07-06 | 2019-04-09 | Tokyo Electron Limited | Heated stage with variable thermal emissivity method and apparatus |
US9932288B2 (en) | 2015-12-09 | 2018-04-03 | West Virginia University | Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent |
JP7039489B2 (ja) * | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
CN112250670B (zh) | 2016-06-07 | 2021-06-08 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
ES2944547T3 (es) | 2017-11-15 | 2023-06-22 | Mirati Therapeutics Inc | Inhibidores de KRas G12C |
-
2019
- 2019-12-05 CN CN201980077511.4A patent/CN113164418A/zh active Pending
- 2019-12-05 EP EP19893444.0A patent/EP3890716A4/en active Pending
- 2019-12-05 KR KR1020217008639A patent/KR20210113587A/ko unknown
- 2019-12-05 MX MX2021002804A patent/MX2021002804A/es unknown
- 2019-12-05 AU AU2019392683A patent/AU2019392683A1/en active Pending
- 2019-12-05 US US17/275,181 patent/US20220079947A1/en active Pending
- 2019-12-05 WO PCT/US2019/064707 patent/WO2020118066A1/en unknown
- 2019-12-05 EA EA202190630A patent/EA202190630A1/ru unknown
- 2019-12-05 JP JP2021513314A patent/JP2022509724A/ja active Pending
- 2019-12-05 CA CA3112129A patent/CA3112129A1/en active Pending
- 2019-12-05 SG SG11202102357RA patent/SG11202102357RA/en unknown
-
2021
- 2021-03-09 IL IL281348A patent/IL281348A/en unknown
- 2021-03-25 ZA ZA2021/02016A patent/ZA202102016B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022509724A (ja) | 2022-01-24 |
EP3890716A1 (en) | 2021-10-13 |
KR20210113587A (ko) | 2021-09-16 |
IL281348A (en) | 2021-04-29 |
WO2020118066A1 (en) | 2020-06-11 |
ZA202102016B (en) | 2022-06-29 |
EP3890716A4 (en) | 2022-12-21 |
SG11202102357RA (en) | 2021-04-29 |
CA3112129A1 (en) | 2020-06-11 |
CN113164418A (zh) | 2021-07-23 |
US20220079947A1 (en) | 2022-03-17 |
EA202190630A1 (ru) | 2021-10-11 |
AU2019392683A1 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021002804A (es) | Terapias de combinacion. | |
PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2021002805A (es) | Terapias de combinacion. | |
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
MX2021014177A (es) | Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. | |
MX2020011907A (es) | Inhibidores de kras g12c para el tratamiento de cancer. | |
ZA202007007B (en) | Mcl-1 inhibitors | |
MX2022003537A (es) | Terapias de combinacion. | |
MX2019011431A (es) | Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1). | |
MA48772B1 (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
PH12020551464A1 (en) | Cd73 inhibitors | |
PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
MX2020011684A (es) | Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer. | |
MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
MX2020013805A (es) | Derivados de piridopirimidinona para uso como inhibidores de axl. | |
MX2022006179A (es) | Derivados macrociclicos de indol como inhibidores de mcl-1. | |
MX2022005400A (es) | Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos. | |
MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. |